REPL Replimune Group, Inc.

NEUTRAL Impact: 4/10 Insider Cluster (3 insiders)
Horizon immediate Filed May 20, 2026 Processed 23d 17h ago
Insider cluster: 3 insiders, $0.3M total
Latest settled — T+5d
REPL ▲ +66.48% at T+5d
NEUTRAL call ✓ call won +66.48% · α vs SPY +64.63% · entry $5.22 → $8.69
Next anchor: T+20d in 5d
Currently $8.88 · +70.11% from $5.22 entry
Entry anchored
May 20, 2026
via day open
T+1d
-5.94%
call -5.94% · α -6.38%
$4.91
settled 23d ago
T+5d
+66.48%
call +66.48% · α +64.63%
$8.69
settled 16d ago
T+20d
call — · α —
in 5d
T+60d
call — · α —
in 2mo

Price Chart

Loading chart...

Executive Summary

Three REPL insiders (CEO, CFO, and a director) sold a total of $319K in open-market sales on May 18, 2026, all at $5.08 per share. The CEO's sale of $190K is the largest, and the cluster timing is identical across all three, suggesting a coordinated or programmatic exit rather than opportunistic selling based on fresh negative information.

Key Financial Metrics

Direction
selling
Total Value
$319.0K
Insiders
3

Actionable Insight

The identical execution price and date across CEO/CFO/director sales suggest a pre-arranged plan or blackout-window opening rather than reactive selling. At 0.08% of market cap, these volumes are noise. However, the CEO's sale of ~$190K is the largest single insider transaction in the trailing 30 days — monitor for any material 8-K or pipeline update within the next two weeks that might have prompted the timing.

Key Facts

  • CEO Patel Sushil sold 37,324 shares for $190K
  • CFO Hill Emily Luisa sold 7,812 shares for $40K
  • Director Astley-Sparke Philip sold 17,657 shares for $90K
  • All three trades executed at $5.08 on May 18, 2026
  • Total cluster value $319K represents 0.08% of $388M market cap
  • No open-market purchases in the cluster — all sales

Financial Impact

$319K total insider sales, below 0.1% of market cap — trivial relative to company size

insider ownershipfloat

Risk Factors

  • CEO sold the largest dollar amount — insider confidence signal worth tracking
  • No insider buying to offset the selling — one-sided signal
  • REPL has a 59% bearish analyst consensus — selling could amplify existing negative sentiment

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
8% bullish (13 analysts)

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-REPL-1779308220177
6 reports for REPL
Performance horizon
100% Hit rate 4 of 4 directional calls best @ T+5▲ +14.84%May 29, 2026
Filters
Rows
Reports for REPL — sortable, filterable
Type Now
Jun 11, 2026
2d ago
Institutional Cluster
BEARISH ★ 4/10
$8.46 awaiting T+5awaiting T+5$8.88 (−4.96%)
May 31, 2026
13d ago
Press Release
BULLISH ★ 6/10
$9.00 $9.47▲ +5.22%▲ +7.97%$8.88 (−1.33%)
May 30, 2026
14d ago
Press Release
BULLISH ★ 8/10
$9.00 $9.47▲ +5.22%▲ +7.97%$8.88 (−1.33%)
May 29, 2026
15d ago
8-K
BULLISH ★ 7/10
$8.69 $9.98▲ +14.84%▲ +15.14%$8.88 (+2.19%)
May 29, 2026
15d ago
Press Release
BULLISH ★ 8/10
$8.69 $9.98▲ +14.84%▲ +15.14%$8.88 (+2.19%)
May 20, 2026
23d ago
Insider Cluster
NEUTRAL ★ 4/10
$5.22 $8.69▲ +66.48%▲ +64.63%$8.88 (+70.11%)
Showing 6 of 6

US Market Status

Market Closed — Opens Mon (47h 29m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access